News

Search:

J&J Antibiotic Approved Via 'Animal Rule' Pathway

0 Likes

After being backed by a US Food and Drug Administration (FDA) advisory committee, life sciences manufacturer Johnson & Johnson (J&J) has won FDA approval for Levaquin (levofloxacin), an antibiotic Read More...

Tags:

Animal

Animal Rule

J&J

JNJ

Johnson & Johnson

Levaquin

Plague

Pneumonic

AstraZeneca CEO Out as New J&J CEO Takes the Helm

0 Likes

Two life sciences giants are experiencing transitions in leadership, as AstraZeneca’s Chief Executive Office David Brennan announced he was relinquishing his position effective immediately and Read More...

Tags:

AstraZeneca

Brennan

CEO

CFO

Gorsky

Head

J&J

JNJ

Johnson

Leadership

Lowth

Weldon

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

Public Warms to FDA in Recent Gallup Poll 28 May 2013
FDA Finalizes Changes to Orphan Drug Regulation, With Emphasis on Clarifying Existing Policies 11 June 2013
Warning Letter to Company Cites Low Supplies of Toilet Paper 15 May 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013
Interview: FDA's UDI Architect Jay Crowley on the Agency's Approach to UDI and Pending Changes 2 May 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New Legislation Seeks Creation of Provisional Approval Pathway for New Drugs 23 May 2013
New FDA Draft Guidance Aims to Clarify Compassionate Use Process 9 May 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

J&J Antibiotic Approved Via 'Animal Rule' Pathway

AstraZeneca CEO Out as New J&J CEO Takes the Helm

Get RF Today